Blogger Facebook Twitter You Tube RSS

Anti-Cancer Compounds

The American Cancer Society has estimated that in 2009, there were 1.5 million new cases of cancer in the United States alone. Excessive signaling in the Hedgehog signaling pathway has been shown to be associated with various types of human cancers. Cyclopamine is a known inhibitor of the Hedgehog signaling pathway, and can be used to regulate cell growth and apoptosis in the treatment of various cancers. However, cyclopamine itself has hindered activity as a drug due to limited solubility. Researchers at Utah State University have developed novel cyclopamine derivatives that exhibit greater solubility and anticancer activity than cyclopamine. These compounds have enhanced utility as drugs and are useful in the treatment of a variety of cancers.
Features and Benefits
  • Pharmaceutical compounds having ability to treat a broad range of cancers:
    • Prostate
    • Lung
    • Gastrointestinal tract
    • Lymphatic system
    • Skin
    • Brain
    • Bone
    • Breast
    • Liver
    • Pancreas
    • Colon
  • Increased solubility over cyclopamine gives the compounds greater effectiveness as drugs
  • Useful in the treatment of a wide range of cancers through inhibition of the Hedgehog Signaling Pathway
  • Capability of being systemically or locally administered gives multiple drug delivery options
The anticancer agents are cyclopamine derivatives that have greater solubility than previous cyclopamines, giving them enhanced utility as drugs. These cyclopamine derivatives have demonstrated usefulness in the treatment of a broad range of cancers.
Development Stage
Reduced proliferation of cancerous human cell cultures has been shown (MTS assay), with more anticancer activity exhibited from a novel cyclopamine derivative. Foundational evidence established for further study of anticancer activity.
US Patent Pending, PCT application filed
Berry Treat
Senior Commercialization Associate
Life Sciences
(435) 797-4569
Reference: W08053